Bluebird bio Inc (BLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bluebird bio Inc (BLUE) has a cash flow conversion efficiency ratio of 0.751x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.44 Million) by net assets ($-57.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bluebird bio Inc (BLUE) net asset quality to measure how much of total assets are equity-financed.
Bluebird bio Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Bluebird bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bluebird bio Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Bluebird bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluebird bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quartiers Properties AB
ST:QUART
|
0.048x |
|
Helbor Empreendimentos S.A
SA:HBOR3
|
0.012x |
|
Feytech Holdings Berhad
KLSE:5322
|
0.054x |
|
QTC Energy Public Company Limited
BK:QTC
|
-0.052x |
|
Rotork PLC
LSE:ROR
|
0.070x |
|
Jourdeness Group Ltd
TW:4190
|
0.101x |
|
SEOHAN Const. & Eng.co.Ltd
KQ:011370
|
-0.091x |
|
Uniflex Technology Inc
TW:3321
|
0.050x |
Annual Cash Flow Conversion Efficiency for Bluebird bio Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Bluebird bio Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Bluebird bio Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.53 Million | $-260.02 Million | 8.246x | +782.46% |
| 2023-12-31 | $194.54 Million | $-235.05 Million | -1.208x | +32.79% |
| 2022-12-31 | $196.34 Million | $-352.95 Million | -1.798x | -5.85% |
| 2021-12-31 | $374.28 Million | $-635.64 Million | -1.698x | -389.27% |
| 2020-12-31 | $1.36 Billion | $-470.35 Million | -0.347x | +20.97% |
| 2019-12-31 | $1.28 Billion | $-564.38 Million | -0.439x | -100.26% |
| 2018-12-31 | $1.89 Billion | $-413.43 Million | -0.219x | -26.91% |
| 2017-12-31 | $1.62 Billion | $-280.55 Million | -0.173x | +20.77% |
| 2016-12-31 | $869.44 Million | $-189.65 Million | -0.218x | -88.48% |
| 2015-12-31 | $850.50 Million | $-98.43 Million | -0.116x | +4.76% |
| 2014-12-31 | $491.26 Million | $-59.69 Million | -0.122x | -142.41% |
| 2013-12-31 | $151.67 Million | $43.45 Million | 0.286x | -24.11% |
| 2012-12-31 | $-55.75 Million | $-21.04 Million | 0.377x | +72.13% |
| 2011-12-31 | $-55.71 Million | $-12.22 Million | 0.219x | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more